News
LXRX
1.640
-2.96%
-0.050
Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024
Lexicon Pharmaceuticals, Inc. Will participate in the Jefferies Global Healthcare Conference on June 5, 2024. The company will be participating in a moderated discussion. Lexicon will be presenting at the conference in New York City on Wednesday, June 4, 2024, at 3:00 p.m.
Barchart · 1d ago
Lexicon Pharmaceuticals: Blue Sky Aplenty, Revenue Not So Much
Seeking Alpha · 2d ago
Weekly Report: what happened at LXRX last week (0520-0524)?
Weekly Report · 3d ago
Weekly Report: what happened at LXRX last week (0513-0517)?
Weekly Report · 05/20 09:21
NEW POST-HOC ANALYSIS OF POOLED PHASE 3 DATA SHOWS THAT INPEFA® (SOTAGLIFLOZIN) REDUCED RISK OF HEART FAILURE EVENTS IN PATIENTS WITH PRESERVED EJECTION FRACTION
Reuters · 05/14 11:02
Lexicon Pharmaceuticals Inc: Statement of changes in beneficial ownership of securities
Press release · 05/14 03:07
Weekly Report: what happened at LXRX last week (0506-0510)?
Weekly Report · 05/13 09:22
Weekly Report: what happened at LXRX last week (0429-0503)?
Weekly Report · 05/06 09:24
Lexicon Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Lexicon Pharmaceuticals Inc reports results for the quarter ended in March. The company reported a quarterly adjusted loss of 20 cents per share. Revenue rose 4,608.3% to $1.13 million from a year ago. The average analyst rating on the company's shares is "buy"
Reuters · 05/03 19:53
Needham Reiterates Hold on Lexicon Pharmaceuticals
Benzinga · 05/03 12:25
Analysts Are Bullish on These Healthcare Stocks: Cigna (CI), Lexicon Pharmaceuticals (LXRX)
TipRanks · 05/03 12:11
Optimistic Buy Rating for Lexicon Pharmaceuticals Amid Strong Inpefa Sales Outlook and Efficient Financial Management
TipRanks · 05/03 10:52
Needham Keeps Their Hold Rating on Lexicon Pharmaceuticals (LXRX)
TipRanks · 05/03 10:33
LXRX Stock Earnings: Lexicon Pharmaceuticals Meets EPS, Misses Revenue for Q1 2024
Lexicon Pharmaceuticals reported earnings per share of -20 cents for the first quarter of 2024. The company reported revenue of $1.13 million. This was 17.52% worse than the analyst estimate for revenue of -16 million. Lexicon reported results for the same period in 2013.
Investorplace · 05/03 00:59
Lexicon Pharmaceuticals, Inc. Quarterly Report for the Period Ended March 31, 2024
Press release · 05/02 22:28
LEXICON PHARMACEUTICALS INC - AS OF MARCH 31, 2024, LEXICON HAD $355.6 MILLION IN CASH AND INVESTMENTS
Reuters · 05/02 20:43
Lexicon Pharmaceuticals GAAP EPS of -$0.20 in-line, revenue of $1.13M misses by $0.27M
Seeking Alpha · 05/02 20:32
Lexicon Pharmaceuticals Q1 2024 GAAP EPS $(0.20), Inline, Sales $1.130M Miss $1.401M Estimate
Lexicon Pharmaceuticals reported quarterly losses of $0.20 per share. The company reported quarterly sales of $1.130 million which missed the analyst consensus estimate by 19.33%. The company also reported a 17.65 percent decrease in sales from the same period last year.
Benzinga · 05/02 20:07
*Lexicon Pharma 1Q Loss $48.4M >LXRX
Dow Jones · 05/02 20:05
Press Release: Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update Commercial launch of INPEFA (sotagliflozin) for Heart Failure continues to progress. Resubmission of NDA for ZYNQUISTA in Type 1 Diabetes expected mid-year 2024. Enrollment in a Phase 2b study of LX9211 in diabetic peripheral neuropathic pain on track.
Dow Jones · 05/02 20:05
More
Webull provides a variety of real-time LXRX stock news. You can receive the latest news about Lexicon Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About LXRX
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.